02/25/2019
https://congress.gov...
"Today's hearing focuses on an area of longstanding concern to this committee that has taken on increased importance: The safety and effectiveness of pharmaceutical products made in foreign countries."
"data challenges we identified in our 2008 report continue to make it difficult for FDA to accurately identify establishments subject to inspection."
"This hearing should not be interpreted as an indictment of foreign drug manufacturing generally."
"I think that'd be really helpful."